<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>319</serviceExecutionTime><Drug id="12227"><DrugName>lactoferrin peptides (HCV), AM-Pharma/XTL</DrugName><DrugSynonyms><Name><Value>GPX-400</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>hLF, Pharming</Value></Name><Name><Value>lactoferrin, Pharming</Value></Name><Name><Value>lactoferrin peptides (HCV), AM-Pharma/XTL</Value></Name></DrugSynonyms><CompanyOriginator id="26342">Pharming NV</CompanyOriginator><CompaniesSecondary><Company id="22124">XTL Biopharmaceuticals Ltd</Company><Company id="24320">Pharming Group NV</Company><Company id="24690">Gem Pharmaceuticals LLC</Company><Company id="30100">AM-Pharma Holding BV</Company></CompaniesSecondary><CrossReferences><SourceEntity id="12227" type="Drug"><TargetEntity id="457535" type="siDrug">GPX-400</TargetEntity></SourceEntity><SourceEntity id="22124" type="Company"><TargetEntity id="4295875163" type="organizationId">X T L Biopharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="24320" type="Company"><TargetEntity id="4295884868" type="organizationId">Pharming Group NV</TargetEntity></SourceEntity><SourceEntity id="24690" type="Company"><TargetEntity id="4297052486" type="organizationId">Gem Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="26342" type="Company"><TargetEntity id="5000841890" type="organizationId">Genzyme Capital NV</TargetEntity></SourceEntity><SourceEntity id="30100" type="Company"><TargetEntity id="5000094629" type="organizationId">AM Pharma Holding BV</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"></TargetEntity><TargetEntity id="D019698" type="MeSH"></TargetEntity><TargetEntity id="-776640207" type="omicsDisease"></TargetEntity><TargetEntity id="430" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="552" type="ciIndication"><TargetEntity id="10055798" type="MEDDRA"></TargetEntity><TargetEntity id="D006470" type="MeSH"></TargetEntity><TargetEntity id="-1283225934" type="omicsDisease"></TargetEntity><TargetEntity id="327" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="577" type="ciIndication"><TargetEntity id="10017964" type="MEDDRA"></TargetEntity><TargetEntity id="904" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="747" type="ciIndication"><TargetEntity id="10060968" type="MEDDRA"></TargetEntity><TargetEntity id="D001170" type="MeSH"></TargetEntity><TargetEntity id="-1191643844" type="omicsDisease"></TargetEntity><TargetEntity id="726" type="siCondition"></TargetEntity><TargetEntity id="722" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1742" type="Action"><TargetEntity id="685" type="Mechanism">Heparin Neutralizers</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="153">Hepatitis C virus infection</Indication><Indication id="552">Bleeding</Indication><Indication id="577">Gastrointestinal infection</Indication><Indication id="747">Infectious arthritis</Indication><Indication id="758">Multidrug resistant infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="991">Antiviral</Action><Action id="1742">Heparin antagonist</Action><Action id="1596">Immunomodulator</Action><Action id="1594">Antibacterial</Action></ActionsSecondary><Technologies><Technology id="66">Antibiotic</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2017-12-04T13:55:35.000Z</LastModificationDate><ChangeDateLast>2017-02-21T00:00:00.000Z</ChangeDateLast><AddedDate>1996-05-01T15:31:27.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22124" linkType="Company"&gt;XTL Biopharmaceuticals&lt;/ulink&gt; and &lt;ulink linkID="30100" linkType="Company"&gt;AM-Pharma&lt;/ulink&gt; were investigating recombinant human lactoferrin (hLF), a naturally occurring antimicrobial present in human breast milk licensed from Pharming, for the potential treatment of hepatitis C virus (HCV) infection [&lt;ulink linkID="399310" linkType="reference"&gt;399310&lt;/ulink&gt;], [&lt;ulink linkID="389703" linkType="reference"&gt;389703&lt;/ulink&gt;], [&lt;ulink linkID="433818" linkType="reference"&gt;433818&lt;/ulink&gt;]. In August 2003, the program was still listed as ongoing [&lt;ulink linkID="504134" linkType="reference"&gt;504134&lt;/ulink&gt;]; however, by early September 2003, XTL was no longer listed as a partner [&lt;ulink linkID="504136" linkType="reference"&gt;504136&lt;/ulink&gt;], [&lt;ulink linkID="504137" linkType="reference"&gt;504137&lt;/ulink&gt;], and AM-Pharma no longer listed the program as active [&lt;ulink linkID="504135" linkType="reference"&gt;504135&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="30100" linkType="Company"&gt;AM-Pharma&lt;/ulink&gt; is investigating a lactoferrin peptide, &lt;ulink linkID="32914" linkType="Drug"&gt;hLF 1-11&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;The product had previously reached phase II trials for gastrointestinal (GI) infections, and phase I trials in infectious arthritis, with originator Pharming [&lt;ulink linkID="312921" linkType="reference"&gt;312921&lt;/ulink&gt;]. &lt;ulink linkID="30100" linkType="Company"&gt;AM-Pharma&lt;/ulink&gt; acquired ownership of the peptide technology in February 2001 [&lt;ulink linkID="399310" linkType="reference"&gt;399310&lt;/ulink&gt;], [&lt;ulink linkID="433818" linkType="reference"&gt;433818&lt;/ulink&gt;]. At this time, is was assumed that Pharming had terminated its involvement in the program; this was confirmed in August 2001 when Pharming filed for receivership [&lt;ulink linkID="420400" linkType="reference"&gt;420400&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In June 1999, Pharming initiated a phase I trial to assess the safety of iv administration of recombinant lactoferrin in healthy volunteers as well as lactoferrin's ability to neutralize heparin [&lt;ulink linkID="329802" linkType="reference"&gt;329802&lt;/ulink&gt;]. Results showed that recombinant lactoferrin was very well tolerated up to high doses [&lt;ulink linkID="387684" linkType="reference"&gt;387684&lt;/ulink&gt;], [&lt;ulink linkID="399308" linkType="reference"&gt;399308&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In February 2001, Pharming's animal model studies demonstrated that both intact hLF and hLF-derived peptides are highly effective against infections with several antibiotic resistant S aureus strains, including methicillin- and &lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt;-resistant strains and Klebsiella pneumoniae [&lt;ulink linkID="399308" linkType="reference"&gt;399308&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By August 2003, &lt;ulink linkID="30100" linkType="Company"&gt;AM-Pharma&lt;/ulink&gt; was collaborating with Biomet-Merck on adding the hLF peptide to orthopedic devices and bone cement for the prevention and treatment of osteomyelitis and other post-surgery bacterial infections [&lt;ulink linkID="504136" linkType="reference"&gt;504136&lt;/ulink&gt;], [&lt;ulink linkID="504135" linkType="reference"&gt;504135&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2000, Pharming and XTL Biopharmaceuticals reached a codevelopment agreement relating to the use of lactoferrin for the treatment of HCV infection [&lt;ulink linkID="389703" linkType="reference"&gt;389703&lt;/ulink&gt;]; however, when Pharming filed for receivership in August 2001, its development of this program was suspended [&lt;ulink linkID="420400" linkType="reference"&gt;420400&lt;/ulink&gt;]. At this time, it was unclear whether XTL was continuing to investigate lactoferrin, and in November 2001, the company confirmed that it was still deciding how to proceed; later in December, XTL extended its research program with &lt;ulink linkID="30100" linkType="Company"&gt;AM-Pharma&lt;/ulink&gt;. This new agreement granted XTL an option to take up an exclusive worldwide license to the lactoferrin peptide for the HCV indication, pending further studies in XTL's proprietary in vivo testing system [&lt;ulink linkID="429204" linkType="reference"&gt;429204&lt;/ulink&gt;], [&lt;ulink linkID="433818" linkType="reference"&gt;433818&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1998, Gem Pharmaceuticals and Pharming had formed a collaboration to develop the use of lactoferrin in open heart surgery; Gem named the drug GPX-400. The companies were to develop and commercialize lactoferrin as a heparin-neutralizing agent. Gem expected to initiate clinical studies for this indication in 1999, with a product launch expected in 2001 [&lt;ulink linkID="307496" linkType="reference"&gt;307496&lt;/ulink&gt;]. In August 2001, Gem confirmed that it sold its rights to this program back to Pharming in 1999 [&lt;ulink linkID="420421" linkType="reference"&gt;420421&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Lactoferrin was developed to be produced in genetically engineered cows, in a collaboration with Pharming and &lt;ulink linkID="21907" linkType="Company"&gt;NV Verenigde Bedrijven Nutricia&lt;/ulink&gt;, a nutrition specialist [&lt;ulink linkID="223959" linkType="reference"&gt;223959&lt;/ulink&gt;]. In January 2000, a patent relating to the purification of human lactoferrin from milk was issued to Pharming in New Zealand [&lt;ulink linkID="377560" linkType="reference"&gt;377560&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24320">Pharming Group NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-08-28T00:00:00.000Z</StatusDate><Source id="420400" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24320">Pharming Group NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="758">Multidrug resistant infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-08-28T00:00:00.000Z</StatusDate><Source id="420400" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24320">Pharming Group NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="577">Gastrointestinal infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-08-28T00:00:00.000Z</StatusDate><Source id="420400" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22124">XTL Biopharmaceuticals Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-02T00:00:00.000Z</StatusDate><Source id="504136" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24320">Pharming Group NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="747">Infectious arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-08-28T00:00:00.000Z</StatusDate><Source id="420400" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24690">Gem Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="552">Bleeding</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-11-01T00:00:00.000Z</StatusDate><Source id="420421" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30100">AM-Pharma Holding BV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22124">XTL Biopharmaceuticals Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-11-15T00:00:00.000Z</StatusDate><Source id="389703" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24320">Pharming Group NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="758">Multidrug resistant infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-02-19T00:00:00.000Z</StatusDate><Source id="399308" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24320">Pharming Group NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-11-15T00:00:00.000Z</StatusDate><Source id="389703" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24320">Pharming Group NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="747">Infectious arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-01-29T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24320">Pharming Group NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="577">Gastrointestinal infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-01-29T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24320">Pharming Group NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="577">Gastrointestinal infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-07-06T00:00:00.000Z</StatusDate><Source id="291044" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30100">AM-Pharma Holding BV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-02-16T00:00:00.000Z</StatusDate><Source id="399310" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24690">Gem Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="552">Bleeding</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-11-01T00:00:00.000Z</StatusDate><Source id="307496" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00142"><Name>Antithrombin III</Name><SwissprotNumbers><Swissprot>P01008</Swissprot><Swissprot>P32261</Swissprot><Swissprot>P32262</Swissprot><Swissprot>P41361</Swissprot><Swissprot>P81050</Swissprot><Swissprot>Q03352</Swissprot><Swissprot>Q5R5A3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1038946">Groupe Danone SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1045361">MedCell Bioscience Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1106763">Zimmer Biomet Holdings Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22124">XTL Biopharmaceuticals Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="24320">Pharming Group NV</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="24690">Gem Pharmaceuticals LLC</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="30100">AM-Pharma Holding BV</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>2</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="116048" title="AM-Pharma to license Pharming's lactoferrin-derived peptides    "></Deal><Deal id="122878" title="Gem Pharmaceuticals and Pharming to codevelop lactoferrin for open heart surgery"></Deal><Deal id="122880" title="Pharming and XTL Biopharmaceuticals to codevelop lactoferrin for the treatment of hepatitis C virus infection"></Deal><Deal id="122881" title="XTL Biopharmaceuticals to acquire an option to develop AM-Pharma's lactoferrin peptide for hepatitis C virus infection worldwide"></Deal><Deal id="122883" title="AM-Pharma and Biomet-Merck to collaborate on adding hLF peptide to orthopedic devices and bone cement  "></Deal><Deal id="126519" title="Pharming and NovaThera to combine NovaThera's biomaterials with Pharming's recombinant proteins   "></Deal><Deal id="126567" title="Pharming and Verenigde Bedrijven Nutricia to jointly produce hLF in genetically engineered cows  "></Deal></Deals><PatentFamilies><PatentFamily id="1126007" number="WO-09203917" title="Homologous recombination in mammalian cells."></PatentFamily><PatentFamily id="1496005" number="WO-09108216" title="Production Of Recombinant Polypeptides By Bovine Species And Transgenic Methods"></PatentFamily><PatentFamily id="1652605" number="WO-09522258" title="Isolation of lactoferrin from milk."></PatentFamily><PatentFamily id="1975023" number="WO-09833509" title="Useful properties of human lactoferrin and variants thereof."></PatentFamily><PatentFamily id="2049506" number="WO-00172322" title="High Dosage Parenteral Administration Of Lactoferrin"></PatentFamily><PatentFamily id="2344151" number="WO-00134641" title="Antimicrobial activity of the first cationic cluster of human lactoferrin"></PatentFamily><PatentFamily id="257544" number="WO-2008023165" title="Composite material"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Groupe Danone SA" id="1038946"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aslan Group AS" id="1043997"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MedCell Bioscience Ltd" id="1045361"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PPL Therapeutics plc" id="19076"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="XTL Biopharmaceuticals Ltd" id="22124"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharming Group NV" id="24320"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gem Pharmaceuticals LLC" id="24690"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LFB SA" id="25256"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dompe Group" id="26028"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AM-Pharma Holding BV" id="30100"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>